GE (GE) Sale of BioPharma Unit 'Additive' to SOTP - Cowen
- Wall Street closes rollercoaster week sharply lower
- Invesco (IVZ) Reportedly in Talks to Merge With State Street's (STT) Asset Management Business, Citi Sees More Cons than Pros
- FDA Votes "No" on Pfizer (PFE) Booster for 16+ Age Group, 2 Yes 16 No
- Jefferies Raises Price Targets on Alphabet (GOOGL) and Facebook (FB) as They Are Still Inexpensive Relative to Growth, Reiterates Snap (SNAP) as a Best Growth Idea
- Tesla (TSLA) Could Deliver 900K EV Units This Year and 1.3M in 2022 - Wedbush
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Cowen analyst Gautam Khanna weighed in on General Electric (NYSE: GE) after the company agreed to sell BioPharma unit to Danaher for $21.4 billion in cash. He said the valuation is 'additive' to Healthcare's SOTP.
"GE's BioPharma sale to DHR fetched a rich valuation that goes a long way towards GE's debt reduction and therefore, suggests upside to our SOTP math around GE's Healthcare exit," Khanna commented. "The stock should react well to the deal. Moreover, GE posted its event calendar, & now plans its outlook call for 3/14."
The firm maintained a Market Perform rating and price target of $8.00
Shares of General Electric closed at $11.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- General Electric's (GE) Power Division is an Overlooked Key Segment in Turnaround - UBS
- United Internet AG (UTDI:GR) PT Raised to EUR45 at Barclays
- The Hut Group (THG:LN) PT Lowered to GBP8.85 at Barclays
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesCowen & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!